Pharmacyclics (PCYC) will collaborate with a JNJ subsidiary to develop and commercialize an oral...
Pharmacyclics (PCYC) will collaborate with a JNJ subsidiary to develop and commercialize an oral treatment of non-Hodgkins lymphoma, chronic lymphocytic leukemia and multiple myeloma. But RBC Capital cuts its recommendation, noting near-term upside may be limited in 2012 given the vastly reduced probability that PCYC will be acquired. PCYC -8% premarket.
From other sites
at CNBC.com (Jan 13, 2015)
at CNBC.com (Dec 5, 2014)
at CNBC.com (Sep 17, 2014)
at CNBC.com (Jul 29, 2014)
at CNBC.com (Jul 23, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs